ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Vall d'Hebron University Hospital at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Vall d'Hebron University Hospital takes part in 38 sessions at ESMO 2026 in Madrid. Its program covers gastrointestinal cancers and precision treatment, alongside breast, lung and other cancers. It examines whether circulating tumour DNA monitoring can help predict treatment response in pancreatic cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Vall d'Hebron University Hospital Barcelona, Spain | |
Public university hospital in Barcelona, Spain, whose campus includes a dedicated oncology research institute, the Vall d'Hebron Institute of Oncology. | Satellite Fri Oct 23 09:45–11:15 Satellite Fri Oct 23 10:30–10:50 Building on Established IO to Reach New Heights Lung & thoracic cancers Satellite Fri Oct 23 10:50–11:10 Keeping the Patient in the Center Lung & thoracic cancers Poster Fri Oct 23 13:00–15:00 A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line (1L) treatment of PD-L1-positive, recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01 Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Association of an immune gene expression signature with clinical outcomes in patients (pts) with advanced gastroesophageal adenocarcinoma (GEA) treated with first-line immunotherapy (IO) Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Neuro-oncology and molecular tumor boards in Latin America: A public–private comparison from the RIANO survey Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Sex as a determinant of molecular profile and therapeutic biomarker landscape in early-onset gastric adenocarcinoma Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 The value of liquid biopsy (LB) in pleural mesothelioma (PM) as a biomarker strategy in clinical trials selection Lung & thoracic cancersBiomarkers & precision oncology Talk Fri Oct 23 13:30 Abstract Fri Oct 23 14:07–14:12 699RO - Dose escalation of Debio 0123 (zedoresertib) plus temozolomide (TMZ) in patients (pts) with recurrent or progressive glioblastoma (GBM) Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 Genomic landscape of cancer of unknown primary (CUP): Prognostic stratification through molecular profiling Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Talk Fri Oct 23 16:15–16:35 Diagnostics and risk stratification of newly diagnosed chronic lymphocytic leukemia Haematological malignancies Abstract Fri Oct 23 16:30–16:35 Abstract Fri Oct 23 17:15–17:20 4212RO - Molecular determinants of cabozantinib efficacy in advanced radioiodine- refractory (RAIR) differentiated thyroid cancer (DTC): The GETNE-CABOTHYROID trial Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 08:30–08:45 Targeting the RAS/RAF pathway in CRC: Where do we stand and future perspectives Gastrointestinal cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Association between disease control and patient-reported functioning and quality of life in the ASCENT-03 study Breast cancerNursing & supportive care Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Impact of ctDNA detected BRCA reversion mutations on outcomes of patients (pts) with BRCA-mutated metastatic breast cancer (mBC) treated with antibody-drug conjugates (ADC) Breast cancerBiomarkers & precision oncology Poster Sat Oct 24 12:00–12:45 Satellite Sat Oct 24 13:00–14:30 Satellite Sat Oct 24 13:00–13:05 Welcome & Introductions Breast cancer Satellite Sat Oct 24 13:20–13:40 Anti-EGFR and BRAF inhibitor combinations: The cutting edge of treatment for BRAF mt mCRC Gastrointestinal cancers Satellite Sat Oct 24 13:55–14:25 Exploring the evolving 1L HER2+ BC landscape Breast cancer Satellite Sat Oct 24 14:25–14:30 Close Breast cancer Chair Sat Oct 24 14:45–16:15 Emerging therapies in endocrine and neuroendocrine neoplasms Sarcoma, CNS, head & neck and rare cancers Chair Sat Oct 24 14:45–16:15 Rare GU cancers Genitourinary cancers Talk Sat Oct 24 15:30–15:45 Papillary RCC Genitourinary cancers Talk Sun Oct 25 08:30–08:50 Talk Sun Oct 25 09:00 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Early postoperative recurrence identifies a biologically aggressive KRAS/MAPK-enriched phenotype in cholangiocarcinoma Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Satellite Sun Oct 25 13:00–14:30 Pierre Fabre Laboratories - BRAFV600E-mutant mCRC: Precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:00–13:03 Welcome and introductions Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:03–13:10 The CRC mutational landscape Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:55–14:25 From the clinic: Applying precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 14:25–14:30 Future directions and close Gastrointestinal cancersBiomarkers & precision oncology Chair Sun Oct 25 14:45–16:00 LARC: The essential role of multidisciplinary management of locally advanced rectal cancer Gastrointestinal cancers Talk Sun Oct 25 14:45–15:05 Presentation by Expert Lung & thoracic cancers Talk Sun Oct 25 14:45–14:50 Presentation of case/condition Gastrointestinal cancers Abstract Sun Oct 25 15:55–16:05 Talk Sun Oct 25 16:30–16:45 Chair Sun Oct 25 16:30–18:00 Talk Sun Oct 25 16:55–17:20 Chair Sun Oct 25 18:30–20:00 Talk Sun Oct 25 18:30–18:45 Presentation of a clinical case of a patient with ROS1-rearranged advanced NSCLC Lung & thoracic cancers Abstract Mon Oct 26 11:07–11:17 Abstract Mon Oct 26 11:17–11:27 Talk Mon Oct 26 15:45–16:05 Satellite Mon Oct 26 19:00–19:25 Integrating HER2-Directed Therapies in the Frontline Setting Lung & thoracic cancersBiomarkers & precision oncology |
Find decision makers at Vall d'Hebron University Hospital
Tell us what you sell and we’ll find the people at Vall d'Hebron University Hospital most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction